Kisho

Takeda Pharmaceuticals America, Inc. — Rare Disease Pipeline | Kisho | Kisho

Takeda Pharmaceuticals America, Inc.

Other

Engaged in the development and commercialization of therapies, the company focuses on addressing unmet needs in 14 rare diseases, including acute lymphoblastic leukemia and hypoparathyroidism.

Orphan Designations

FDA Approvals

Rare Diseases

News Articles

Disease	Drug(s)	Designation	Approved
acute lymphoblastic leukemia	ICLUSIG	-	FDA Approved
attention deficit-hyperactivity disorder	MYDAYISVYVANSE	-	FDA Approved
attention deficit-hyperactivity disorder 8	MYDAYIS	-	FDA Approved
attention deficit-hyperactivity disorder, susceptibility to, 1	MYDAYIS	-	FDA Approved
attention deficit-hyperactivity disorder, susceptibility to, 2	MYDAYIS	-	FDA Approved
attention deficit-hyperactivity disorder, susceptibility to, 3	MYDAYIS	-	FDA Approved
attention deficit-hyperactivity disorder, susceptibility to, 4	MYDAYIS	-	FDA Approved
attention deficit-hyperactivity disorder, susceptibility to, 5	MYDAYIS	-	FDA Approved
attention deficit-hyperactivity disorder, susceptibility to, 6	MYDAYIS	-	FDA Approved
attention deficit-hyperactivity disorder, susceptibility to, 7	MYDAYIS	-	FDA Approved
hereditary attention deficit-hyperactivity disorder	MYDAYIS	-	FDA Approved
hypoparathyroidism	NATPARA (PARATHYROID HORMONE)	-	FDA Approved
hypoparathyroidism, familial isolated 1	NATPARA (PARATHYROID HORMONE)	-	FDA Approved
pseudohypoparathyroidism type 1A	NATPARA (PARATHYROID HORMONE)	-	FDA Approved

← Back to Companies